ADCs Prepare for a Comeback: With Potent Drugs and Stable Linker Technology
Cytotoxic drugs appended to antibodies for site specific delivery seems like a smart answer to cancer. The technology, known as Antibody Drug Conjugate is not new to the oncology sector, but, could not realize its true potential until now. Significant advancements in the past few years have fuelled interest in ADCs. This renewed interest in ADCs will have a significant contribution in the growth of the market for cancer mAbs, which is to reach US$ 34 Billion by 2017.
View full press release